Intraductal papillary neoplasms
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients initially diagnosed with IPMN or PCN of undetermined nature by imaging at the First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital from April 1, 2026, to March 1, 2027. 2.Aged 18 to 85 years.
Exclusion criteria
Exclusion criteria: 1. Patients requiring repeat hospital admission for EUS-guided ablation during the study period. 2. Patients with main-duct IPMN (MD-IPMN). 3. Number of cystic lesions >=6. 4. Inability to rule out malignancy (presence of mural nodules, solid components, eggshell calcification of the cyst wall, cystic fluid cytology suggestive of malignancy or high-grade dysplasia, main pancreatic duct dilation >10 mm, or associated symptoms). 5. History of pancreatitis or evidence of pancreatic necrosis. 6. Presence of contraindications to EUS, ERCP, anesthesia, or the use of lauromacrogol. 7.Patients with other comorbid conditions deemed by the investigator to be unsuitable for enrollment, or with a predicted short life expectancy. 8. Pregnant or breastfeeding women. 9. Coagulation dysfunction. 10. Patients who are unwilling or unable to provide informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rates of complications after EUS-guided ablation (Safety); | — |
Secondary
| Measure | Time frame |
|---|---|
| The response rate of IPMN (including complete response and partial response);The incidence of diabetes mellite;The incidence of pancreatic cancer;The incidence of symptoms such as abdominal pain and jaundice ;Incidence and severity of complications throughout the entire treatment process;The success rate of ERCP cannulation ;The success rate of stent placement ;Length of hospital stay and costs;Adverse event;Recurrent pancreatic intraductal papillary mucinous tumor (IPMN); | — |
Countries
China
Contacts
Chinese PLA General Hospital